- NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
- NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
- NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
- NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
- NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
- NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
- NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
- NextCure Provides Business Update and Reports Full Year 2023 Financial Results
- NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
- NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
More ▼
Key statistics
On Wednesday, NextCure Inc (NXTC:NSQ) closed at 1.57, 60.20% above the 52 week low of 0.98 set on Oct 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.59 |
---|---|
High | 1.61 |
Low | 1.49 |
Bid | 1.25 |
Offer | 1.66 |
Previous close | 1.50 |
Average volume | 108.19k |
---|---|
Shares outstanding | 27.97m |
Free float | 25.49m |
P/E (TTM) | -- |
Market cap | 43.92m USD |
EPS (TTM) | -2.29 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼